Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib,CYC202)

Catalog Number:
L002368327APE
Mfr. No.:
APE-A1723
Price:
$228
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Roscovitine, also known as seliciclib or CYC202, is a selective cyclin-dependent kinases (cdk), which are essential cell cycle regulators frequently involved in the deregulation of human tumors, inhibitor that potently inhibits cdc2 (cdc2/cyclin B), cdk2 (cdk2/cyclin A and cdk2/cyclin E) and cdk5 (cdk5/p35) with half maximal inhibition concentration IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM respectively [1].
          Roscovitine has been found to inhibit cellular prophase/metaphase transition at micromolar concentrations, where it inhibits progesterone-induced oocyte maturation of Xenopus oocytes and arrests starfish oocytes and sea urchin embryos in late prophase [1].
          Additionally, roscovitine is capable of inhibiting extracelluar regulated kinases, erk1 and erk2, with IC50 of 34 μM and 14 μM respectively [1].

          [1] Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36.

      • Properties
        • Alternative Name
          (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
          CAS Number
          186692-46-6
          Molecular Formula
          C19H26N6O
          Molecular Weight
          354.45
          Appearance
          A solid
          Purity
          99.04%
          Solubility
          insoluble in H2O; ≥17.72 mg/mL in DMSO; ≥53.5 mg/mL in EtOH
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Daiane J.Viegasa, Terri G.Edwardsb, et al. "Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons." Antiviral Research. Available online 18 October 2019, 104621.
          2. Azimi A, Caramuta S, et al. "Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors." Mol Syst Biol. 2018 Mar 5;14(3):e7858. PMID:29507054
          3. Ruegsegger GN, Toedebusch RG, et al. "Loss of Cdk5 function in the nucleus accumbens decreases wheel running and may mediate age-related declines in voluntary physical activity." J Physiol. 2016 Jul 27. PMID:27461471

    We Also Recommend

    PA-824

    $250

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.